Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

2.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

3.

Erratum to: medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.

Raparelli V, Proietti M, Buttà C, Di Giosia P, Sirico D, Gobbi P, Corrao S, Davì G, Vestri AR, Perticone F, Corazza GR, Violi F, Basili S; ARAPACIS Study Investigators; GIS Group.

Intern Emerg Med. 2015 Mar;10(2):261-5. doi: 10.1007/s11739-014-1166-4. No abstract available.

PMID:
25519853
4.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
5.

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.

Violi F, Daví G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators.

J Am Coll Cardiol. 2013 Dec 10;62(23):2255-6. doi: 10.1016/j.jacc.2013.07.035. Epub 2013 Aug 14. No abstract available.

6.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
7.

Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.

Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, Zhang Y, Assaid C, Mozley LH, Strickler N, Bachman R, Mahoney E, Lines C, Hewitt DJ; Rizatriptan Protocol 082 Pediatric Migraine Study Group.

Cephalalgia. 2012 Jul;32(10):750-65. Epub 2012 Jun 18.

PMID:
22711898
8.

Biophysical stimulation in osteonecrosis of the femoral head.

Leo M, Milena F, Ruggero C, Stefania S, Giancarlo T.

Indian J Orthop. 2009 Jan;43(1):17-21. doi: 10.4103/0019-5413.45319.

9.

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators.

Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74.

PMID:
19204263
10.

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators.

Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21.

PMID:
18208877
11.

Pre-operative evaluation of cervical adenopathies in tumours of the upper aerodigestive tract.

Giancarlo T, Palmieri A, Giacomarra V, Russolo M.

Anticancer Res. 1998 Jul-Aug;18(4B):2805-9.

PMID:
9713465
12.

Distinguishing acyclovir neurotoxicity from encephalomyelitis.

Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM.

J Intern Med. 1993 Nov;234(5):507-11. Review.

PMID:
8228796
13.

Neuromuscular causes of prolonged ventilator dependency.

Spitzer AR, Giancarlo T, Maher L, Awerbuch G, Bowles A.

Muscle Nerve. 1992 Jun;15(6):682-6.

PMID:
1508233
14.

Isolation and partial purification of phthalate ester hydrolyzing enzyme(s) from the brine shrimp, Artemia.

Hudson RA, Giancarlo T 2nd, Austerberry CF, Bagshaw JC.

Toxicol Lett. 1982 Mar;10(4):389-94.

PMID:
7089993

Supplemental Content

Loading ...
Support Center